In the past 25 years — from 2000 to 2024 — we have witnessed a revolution in the management, treatment, and outcome of what used to be the most lethal hematologic cancer: Philadelphia ...

The American Society of Hematology (ASH) released guidelines on frontline management of acute lymphoblastic leukemia (ALL) in adolescents and young adults (AYAs), as well as the management of relapsed ...

Researchers from the Alliance for Clinical Trials in Oncology have found that two targeted immunotherapy drugs lead to high remission rates and long survival with reasonable side effects for older ...

CD123 expression and its correlation with mutation profile in acute myeloid leukemia. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not include a full text ...

CLL is the most common type of leukemia in adults. 3 An estimated 18,500 people were treated for CLL in the 1st-line setting in the US in 2024. 4 Jennifer Brown, MD, PhD, Director of the CLL Center of ...

Phase 1b–2 trial evaluates the potential of CAR T-cell therapy obe-cel in relapsed or refractory B-cell ALL patients. Chimeric antigen receptor (CAR) T-cell therapy has shown promise in inducing ...

The addition of blinatumomab to consolidation chemotherapy in adults with B-cell precursor acute lymphoblastic leukemia who had minimal residual disease–negative status after treatment improved ...

Driven by a steady influx of retirees, Florida now has the highest leukemia rates of any U.S. state and the disease is the fastest-rising cancer type statewide, according to new research from ...

Acute lymphoblastic leukemia (ALL) is known as a pediatric leukemia, with approximately half of cases occurring in children. ALL is the most common childhood malignancy, representing 75% to 80% of ...

The results of Alliance A041703 Cohort 1, published in the Journal of Clinical Oncology, focused on treating patients aged 60 years and older with newly diagnosed B-cell acute lymphoblastic leukemia ...